The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

GSK plc GSK will report its second-quarter earnings on Jul 31, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $9.5 billion and $1.00 per share, respectively.

GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

As we can see above, GSK has delivered a solid quarter of performance, outperforming analysts expectations across most measures, and driven by strong performances from the likes of shingles ...

The investment community will be closely monitoring the performance of GSK in its forthcoming earnings report. The company is expected to report EPS of $0.95, up 5.56% from the prior-year quarter.

GSK's native reporting currency is UK pounds, and shares are traded on the London Stock Exchange. GSK ADS, equivalent to 2 GSK shares, are traded on the NYSE in US$. The underlying performance of ...

GSK plc (NYSE:GSK) is one of the most affordable yet financially rewarding healthcare stocks to buy right now, According to Insider Monkey’s database, 41 hedge funds are bullish on the stock ...

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...